ReviewFrontiers in oncology2026
The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the rapid development of molecular biotechnology and in-depth exploration of bladder cancer (BC) oncogenic mechanisms, targeted therapy has emerged as a pivotal treatment modality for BC patients. This study employed bibliometric methods to analyze the research status and development trends of targeted therapy in BC both domestically and internationally, aiming to identify research hotspots and provide a reference for research layout in this area. Methods: A systematic search was conducted across renowned international and domestic databases, including Web of Science Core Collection (WoSCC), PubMed, Wanfang Database, and the Chinese National Knowledge Infrastructure (CNKI). The search period was limited to 1994-2024, with search terms including "bladder cancer", "targeted therapy", and their related derivatives. After screening, 912 English publications and 328 Chinese publications were included. WPS Excel (v12.1.0) was used to visualize trends in annual publication volume, and CiteSpace (v6.3.R1) was employed for a visual analysis of countries/regions, institutions, authors, journals, cited articles, and keywords related to the included publications. Results: In the field of targeted therapy in BC, the annual publication volume has generally shown an upward trend over the past three decades for both English and Chinese publications, with a faster growth rate observed in English publications. For English publications, the most productive countries/regions, institutions, authors, and journals were the USA, University of Texas System, Dinney CPN, and Urologic Oncology-Seminars and Original Investigations, respectively. The most cited article was "Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma" published in Discussion: Currently, Europe and America dominate the field of targeted therapy in BC. China can leverage its advantage in terms of patient population size to strengthen domestic and international collaborations, thereby enhancing its research influence in this field. Global research hotspots reveal the translational process of targeted therapy in BC from bench to bedside. Future research in this field will focus on drug management of targeted therapy for metastatic BC and overcoming drug resistance to targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.